Advanced search×
×

Clinical Therapeutics

Print ISSN
0149-2918
Electronic ISSN
1879-114X
Impact factor
2.551
Publisher
Sciencedirect
URL
http://www.sciencedirect.com/science/journal/01492918
Usage rank
431
Article count
4656
Free count
20
Free percentage
0.00429553
PDFs via platforms
Gale, Ingenta, Rcgp, and Sciencedirect from 1995

  1. Three-year cost-effectiveness model for non-animal stabilized hyaluronic acid and dextranomer copolymer compared with sacral nerve stimulati...

    Clinical Therapeutics 36(6):890 (2014) PMID 24815061

    Two new therapies for fecal incontinence (FI) are now available: non-animal stabilized hyaluronic acid and dextranomer copolymer (NASHA/Dx) and sacral nerve stimulation (SNS). This study aimed to determine the cost-effectiveness of NASHA/Dx compared with SNS and conservative therapy (CT) for the tre...
  2. Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells.

    Clinical Therapeutics 36(6):847 (2014) PMID 24952935

    Exosomes are small (30- to 100-nm) vesicles secreted by all cell types in culture and found in most body fluids. A mean of 1 mL of blood serum, derived from healthy donors, contains approximately 10(12) exosomes. Depending on the disease, the number of exosomes can fluctuate. Concentration of exosom...
  3. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide...

    Clinical Therapeutics 35(8):1162 (2013) PMID 23911260

    LX4211 is a first-in-class dual inhibitor of sodium-dependent glucose cotransporters 1 and 2 (SGLT1 and SGLT2). SGLT1 is the primary transporter for glucose absorption from the gastrointestinal tract, and SGLT2 is the primary transporter for glucose reabsorption in the kidney. SGLT1 inhibition reduc...
  4. Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines.

    Clinical Therapeutics 35(7):1005 (2013) PMID 23831360

    We selected patients who were being treated following the therapeutic recommendations of the National Osteoporosis Foundation or the guideline for glucocorticoid-induced osteoporosis recommended by the American College of Rheumatology. Adherence was determined by compliance and the persistence ratio...
  5. Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/h...

    Clinical Therapeutics 35(5):673 (2013) PMID 23587606

    Attention deficit/hyperactivity disorder (ADHD) is a heterogeneous behavioral disorder commonly found in children, with serious lifetime health and social consequences for both children and their parents. Public awareness of ADHD in Germany has increased in the past decade, but little is known about...
  6. Collaboration designed to increase translation of diabetes research outcomes into clinical practice.

    Clinical Therapeutics 35(5):712 (2013) PMID 23688535

  7. Impact of local administration of liposome bupivacaine for postsurgical analgesia on wound healing: a review of data from ten prospective, c...

    Clinical Therapeutics 35(3):312 (2013) PMID 23453403

    Liposome bupivacaine is a liposomal formulation that allows delivery of bupivacaine for 96 hours with a single local administration. It is indicated for the management of postsurgical pain. This retrospective review of 10 clinical trials assessed the potential impact of local anesthetics on wound he...
  8. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with...

    Clinical Therapeutics 34(9):1892 (2012) PMID 22884767

    Exenatide once weekly (QW) is an extended-release formulation of exenatide, a glucagon-like peptide-1 receptor agonist that reportedly improves glycemic control in patients with type 2 diabetes. The goal of this study was to test the hypothesis that exenatide QW is noninferior to insulin glargine, a...
  9. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind,...

    Clinical Therapeutics 34(9):1920 (2012) PMID 22917853

    MAP0004 is an orally inhaled investigational drug containing dihydroergotamine (DHE). Although DHE has been used for 60 years with no reported cardiac arrhythmias, a thorough QT study had not previously been performed with DHE. The objective of this study was to assess the effects of MAP0004 on the...
  10. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-co...

    Clinical Therapeutics 34(8):1667 (2012) PMID 22770644

    We examined data collected from the aforementioned trial to compare outcomes in patients who received either oral linezolid or intravenous vancomycin therapy. This study analyzed outcomes in patients who received treatment for 7 to 14 days with either oral linezolid (600 mg q12h; n = 95) or intraven...